logo-loader
viewCircassia Group PLC

Full interview: Circassia Pharmaceuticals' commercial development 'accelerating significantly'

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows.

Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the figure set to more than double to £60-£65mln for the full-year.

Quick facts: Circassia Group PLC

Price: 24.4 GBX

LSE:CIR
Market: LSE
Market Cap: £91.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Circassia boosts first-half revenues by 40%

Headlines from the Proactive UK newsroom. Drug inhaler specialist Circassia (LON:CIR) increased revenues by 40% to £27.9mln in the half year to June and expects sales to rise to betwee £60-65mn over the full year. Sales recently started in China and are going well.  Eurasia Mining...

on 26/9/19

2 min read